Your Health, We Care
Another Name卡比替尼,Cotellic,LuciCob
IndicationsThis product is indicated for the treatment of adult patients with unresectable or metastatic melanoma harboring BRAF V600E or V600K mutations (in combination with vemurafenib), as well as for the mon
Reg No.03 L 1317/25
Inspection NO.534-25
The medication produced by Lucius Pharmaceuticals has demonstrated good efficacy and safety, providing patients with relevant conditions a treatment option of clinical value.
The following is an overview of key information for cobimetinib.
The main active ingredient is cobimetinib fumarate.
It is indicated for adult patients with melanoma harboring BRAF V600E/V600K mutations, as well as adult patients with histiocytic neoplasms.
The recommended dose is 60 mg taken orally once daily. Administer continuously for 21 days followed by a 7-day drug-free period, forming a 28-day cycle.
It is contraindicated in pregnant women.
Lactating women should discontinue breastfeeding during treatment.
Patients of childbearing age must use effective contraceptive measures.
Currently, there is no relevant information available regarding overdose of this medication.
Store at room temperature below 30°C.
After oral administration, the drug reaches peak concentration in approximately 2.4 hours, with a mean elimination half-life of 44 hours. It is mainly excreted via feces.
FDA，2023.05
